- For Print
- May 24, 2010
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that fifteen abstracts highlighting the latest results from studies with its pipeline and portfolio products on metastatic breast cancer, ovarian cancer, non-small cell lung cancer, metastatic brain cancer, T-cell lymphoma and other cancers have been accepted for presentation during the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, United States from June 4 to June 8, 2010.
Among the studies to be presented is an oral presentation of new data from a global phase III study (EMBRACE: Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) of the Company's investigational anticancer agent eribulin mesylate (generic name, “eribulin”). The EMBRACE Study is an open-label, randomized, parallel two-arm, multi-center study of eribulin versus treatment of physicians choice in patients with locally recurrent or metastatic breast cancer previously treated with at least two chemotherapy regimens including an anthracycline and a taxane.
Eisai has long positioned integrative oncology as a therapeutic area of focus and has continued to prioritize the allocation of resources to research and development in this area. The accepted studies collectively reflect the Company's oncology pipeline and product portfolio strategy as well as pre-clinical and clinical oncology research.
Eisai will continue its commitment to actively pursuing the global discovery, development and production of oncology therapies representative of its human health care (hhc) philosophy to increase benefits to patients and their families, thereby making further contributions to addressing the diversified needs of and increasing the benefits to patients and their families as well as healthcare providers.
■The following fourteen abstracts on Eisai's pipeline and portfolio products are accepted for presentation at this year's ASCO meeting:
| Product | Abstract Details | Location Details |
|---|---|---|
Eribulin Mesylate (E7389) |
A phase III study (EMBRACE) of eribulin mesylate versus treatment of physicians choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxaneOral presentation |
June 8, 2010 |
Eribulin Mesylate (E7389) |
Efficacy and safety of eribulin in Japanese patients with advanced breast cancer |
June 5, 2010 |
Eribulin Mesylate(E7389) |
Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors |
June 7, 2010 |
Eribulin Mesylate |
Eribulin mesylate pharmacokinetics in patients with hepatic impairment |
June 7, 2010 |
Farletuzumab |
Efficacy and safety of farletuzamab, a humanized monocolonal antibody to folate receptor alpha, in platinum-sensitive relapsed ovarian cancer subjects: Final data from a multicenter phase II study |
June 7, 2010 |
Farletuzumab |
A randomized, double blind, placebo controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer |
June 7, 2010 |
E7820 |
Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC) |
June 6, 2010 |
Ontak® |
Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial |
June 4, 2010 |
E7080 |
A Phase I dose-escalation study of E7080, a selective tyrosine kinase inhibitor, administered orally to patients with solid tumors |
June 7, 2010 |
E6201 |
A Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid tumors |
June 6, 2010 |
Gliadel® Wafer |
A prospective study of surgery plus biodegradable carmustine wafers for local control and neurocognitive function in 39 patients with one-to- three brain metastases: Preliminary results |
June 6, 2010 |
Dacogen® |
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes (MDS) |
June 5, 2010 |
Dacogen® |
Hematologic outcomes of MDS treatment with hypomethylating agents in community practice |
June 5, 2010 |
Fragmin® |
A real-world evaluation of the effectiveness of dalteparin in the prevention of recurrent venous thromboembolism compared to warfarin in patients with cancer |
June 7, 2010 |
Aloxi® |
Chemotherapy induced nausea and vomiting-associated hospital and ER visits in real-world practice: Palonosetron versus other 5-HT
3-RA anti-emetic regimens |
June 7, 2010 |
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120